Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    ICYMI: Phase 3 Trial Data Available on Lumasiran for Primary Hyperoxaluria type 1
    source: pixabay.com

    ICYMI: Phase 3 Trial Data Available on Lumasiran for Primary Hyperoxaluria type 1

      Earlier this year, the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) held its International Congress. During the Congress, researchers discussed the latest in research and scientific innovation within…

    Continue Reading ICYMI: Phase 3 Trial Data Available on Lumasiran for Primary Hyperoxaluria type 1
    NUZYRA for NTM Lung Disease from MAC Earns Fast Track Designation
    oracast / Pixabay

    NUZYRA for NTM Lung Disease from MAC Earns Fast Track Designation

      In the United States, during the drug development and approval process, drug developers are able to request Fast Track designation. This process is designed to facilitate and expedite the…

    Continue Reading NUZYRA for NTM Lung Disease from MAC Earns Fast Track Designation